Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
A method of treating a disorder in a subject. The method comprises administering to said subject an effective amount of an agonist of the melanocortin-4 receptor (MC4R). The subject is a heterozygous carrier of an MC4R mutation, and the disorder results from an attenuated response of MC4R to α-melanocortin stimulating hormone (α-MSH).
1. A method for treating obesity or a metabolic syndrome in a subject in need thereof, wherein the method comprises administering to said subject an effective amount of Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 (SEQ ID NO: 140) or a pharmaceutically acceptable salt thereof, wherein the subject is a heterozygous carrier of an MC4R mutation.
2. The method of claim 1 , wherein the obesity or metabolic syndrome results from an attenuated response of MC4R to α-melanocortin stimulating hormone (α-MSH).
3. The method of claim 1 , wherein the subject has a mutation in the gene encoding for pro-opiomelanocortin (POMC).
4. The method of claim 1 , wherein the subject has a mutation in the gene encoding for leptin.
5. The method of claim 1 , wherein the method is a method for treating obesity.
6. The method of claim 1 , wherein the method is a method for treating a metabolic syndrome.
7. The method of claim 1 , wherein the subject is a human.
8. The method of claim 1 , wherein the Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 (SEQ ID NO: 140) or a pharmaceutically acceptable salt thereof is an agonist of a melacortin-4 receptor (MC4R).
9. A method for treating obesity or a metabolic syndrome in a subject in need thereof comprising Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 (SEQ ID NO: 140) or a pharmaceutically acceptable salt thereof, wherein the subject has a gene mutation or a gene defect upstream of the melanocortin-4 receptor (MC4R).
10. The method of claim 9 , wherein the gene mutation or a gene defect is related to the gene encoding for pro-opiomelanocortin (POMC).
11. The method of claim 9 , wherein the gene mutation or a gene defect is related to the gene encoding for leptin.
12. The method of claim 9 , wherein the obesity or metabolic syndrome results from an attenuated response of MC4R to α-melanocortin stimulating hormone (α-MSH).
13. The method of claim 9 , wherein the subject is a human.
14. The method of claim 9 , wherein the Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 (SEQ ID NO: 140) or a pharmaceutically acceptable salt thereof is an agonist of a melacortin-4 receptor (MC4R).